EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer

Adam Cole, Daniel A Shoskes, R Jonathan Henderson

Bladder Cancer · 2026-06 · 12 (2)

DOI: 10.1177/23523735261447111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 13.05.2026. Verfasst von Adam Cole und 2 weiteren Autor:innen. Beteiligte Einrichtung: PathNet, Little Rock, AR, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ferring Pharmaceuticals Inc., Parsippany, NJ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concomitant carcinoma in situ (CIS) with high-grade papillary urothelial carcinoma impacts patient risk stratification and treatment. However, on identification of a high-grade papillary lesion, pathologists may be disinclined to search for possible CIS. Several newer agents for bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer (NMIBC) are indicated specifically for patients with CIS ± papillary tumors; hence failure to detect/report CIS may limit treatment options.

Objective

To assess CIS frequency in patients with high-grade Ta/T1 NMIBC.

Methods

In this retrospective cohort study, transurethral resection of bladder tumor biopsy specimens with an accompanying diagnosis of high-grade papillary NMIBC without CIS were identified in the PathNet database (2023–2024) and re-reviewed by a single pathologist for the presence of concomitant CIS.

Results

In total, 316 cases of high-grade papillary urothelial carcinoma (254 Ta, 62 T1 disease) were identified for re-review. Mean patient age was 73 (range 27–93) years; 81.0% of patients were male. On re-review, CIS was identified in 80 cases (25.3%, 95% CI 20.8%–30.4%). CIS frequency was higher in T1 disease (19/62 cases [30.6%]) vs Ta disease (61/254 cases [24.0%]). Among the 8 pathologists who performed the initial review, CIS-positivity rates in their individual biopsy samples varied from 15.0% (6/40) to 66.7% (2/3).

Conclusion

This study suggests that ∼25% of patients with high-grade papillary urothelial carcinoma may have unreported CIS. Close communication between the urologist and pathologist is crucial in ensuring specific exclusion of CIS in all bladder specimens, since a diagnosis of concomitant CIS may impact patient management.

Schlagwörter

Stichwörter der Autor:innen

bladder cancercarcinoma in situdiagnosisepidemiologypapillary urothelial carcinomapathology

Autor:innen und Institutionen

  • PathNet, Little Rock, AR, USA.
  • Ferring Pharmaceuticals Inc., Parsippany, NJ, USA.
  • Arkansas Urology, Little Rock, AR, USA.

Förderung

  • Ferring Pharmaceuticals Inc., Parsippany, NJ

Zitieren

APA

Cole, A., Shoskes, D. A., & Henderson, R. J. (2026). Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer. Bladder Cancer, 12(2). https://doi.org/10.1177/23523735261447111

Vancouver

Cole A, Shoskes DA, Henderson RJ. Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer. Bladder Cancer. 2026;12(2). doi:10.1177/23523735261447111

BibTeX
@article{Cole2026,
  author = {Cole, Adam and Shoskes, Daniel A and Henderson, R Jonathan},
  title = {Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer},
  journal = {Bladder Cancer},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1177/23523735261447111}
}
Kostenlos starten →